We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Testing Could Improve Treatment for Virulent Multidrug-Resistant Fungus Candida Auris

By LabMedica International staff writers
Posted on 07 Jan 2025
Print article
Image: Genetic testing can determine which drugs will work for patients with C. auris (Photo courtesy of Shutterstock)
Image: Genetic testing can determine which drugs will work for patients with C. auris (Photo courtesy of Shutterstock)

Candida auris (C. auris), a multidrug-resistant yeast responsible for severe, life-threatening infections, was first identified in 2009. Since its discovery, it has spread globally, causing significant illness in healthcare settings. With a mortality rate estimated between 30% and 60%, C. auris is not only deadly but also difficult to treat. One of the challenges in managing C. auris infections is the existence of various strains, each with distinct genetic characteristics that confer resistance to different antifungal medications. To identify which drugs are effective against a specific strain, clinical laboratories perform susceptibility testing. This process involves growing a sample of the patient’s C. auris alongside different antifungal drugs to observe which one effectively kills the fungus. However, interpreting these test results can be challenging, as minimum inhibitory concentration (MIC) breakpoints—the lowest concentrations of antifungal drugs that stop C. auris growth—have not been fully defined. Consequently, healthcare providers often face delays in selecting the appropriate antifungal treatment, and such delays can be critical, potentially affecting patient outcomes.

Now, a new study published in ADLM's Clinical Chemistry journal, suggests that genetic testing could provide a faster, more accurate way to identify which antifungal drugs will be effective against C. auris infections. The researchers believe that genetic testing could help doctors initiate the right treatment sooner, improving patient outcomes. To explore this possibility, researchers from Columbia University Irving Medical Center (New York City, NY, USA) examined antifungal resistance genes in C. auris samples from 66 patients. These samples were subjected to two types of genetic analysis: whole-genome sequencing (WGS) and Sanger sequencing. These techniques helped identify each strain’s genetic profile. In addition, the samples underwent traditional susceptibility testing, where they were exposed to seven major antifungal drugs.

By comparing the genetic data with the susceptibility test results, the researchers identified several mutations in the FKS1 gene of C. auris that are responsible for resistance to echinocandins, the primary class of antifungal drugs used to treat invasive C. auris infections. Specifically, they discovered that the Ser639Tyr and Arg135Ser mutations in the FKS1 gene are linked to resistance to micafungin and anidulafungin, while the Met690Ile mutation confers resistance to caspofungin. These findings demonstrate that genomic sequencing can pinpoint which drugs a particular strain of C. auris is resistant to, potentially offering an alternative to traditional susceptibility testing.

“With potential resistance to all three major antifungal classes of drugs, C. auris is an emerging public health threat. Early detection of echinocandin resistance by molecular methods could impact treatment course to include novel antifungal agents,” said Dr. Marie C. Smithgall who led the research team. “Overall WGS serves as a powerful tool for molecular surveillance to help monitor, detect, and curb the spread of C. auris.”

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.